Highlights of This Issue 1187

SPECIAL FEATURES

CCR Translations
1189 PET Imaging of Tumor Growth: Not as Easy as It Looks
Anthony F. Shields
See article p. 1303

1192 Rehabilitation for Oncogene Addiction: Role of Immunity in Cellular Sobriety
David L. Bajor and Robert H. Vonderheide
See article p. 1386

CCR New Strategies
1195 New Strategies in Melanoma: Molecular Testing in Advanced Disease
Scott E. Woodman, Alexander J. Lazar, Kenneth D. Aldape, and Michael A. Davies

Molecular Pathways
1201 Molecular Pathways: Beta-Adrenergic Signaling in Cancer
Steven W. Cole and Anil K. Sood

1207 Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer
Asis Palazón, Julián Aragonés, Aiza Morales-Kastresana, Manuel Ortiz de Landázuri, and Ignacio Melero

Review
1214 Here, There Be Dragons: Charting Autophagy-Related Alterations in Human Tumors
Chandra B. Lebovitz, Svetlana B. Bortnik, and Sharon M. Gorski

HUMAN CANCER BIOLOGY

Activation of PI3K Signaling in Merkel Cell Carcinoma
Valentina Nardi, Youngchul Song, Juan A. Santamaria-Barría, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergthlon, Vanessa L. Scialabba, Hensin Tsao, Jeffrey Settlement, David P. Byan, Darrell R. Borger, Atul K. Bhan, Mai P. Hoang, Anthony J. Iafrate, James C. Cusack, Jeffrey A. Engelman, and Dora Dias-Santagata

Infiltration of Lynch Colorectal Cancers by Activated Immune Cells Associates with Early Staging of the Primary Tumor and Absence of Lymph Node Metastases

HDL of Patients with Type 2 Diabetes Mellitus Elevates the Capability of Promoting Breast Cancer Metastasis
Bing Pan, Hui Ren, Yubin He, Xiaofeng Lv, Yijing Ma, Jing Li, Li Huang, Baoqi Yu, Jian Kong, Chenguang Niu, Youyi Zhang, Wen-bing Sun, and Lemin Zheng

Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival
Evgenia Gubanova, Brandee Brown, Sergei V. Ivanov, Thomas Helleday, Gordon B. Mills, Wendell G. Yarbrough, and Natalia Issaeva

CANCER THERAPY: PRECLINICAL

Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, c-Myb
Takeshi Miyazaki, Yang Pan, Kaushal Joshi, Deepthi Purohit, Bin Hu, Habibe Demir, Sarmistha Mazumder, Sachiko Okabe, Takao Yamori, Mariano Viapiano, Kazuo Shin-ya, Hiroyuki Seimiya, and Ichiro Nakano
SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid Cancer
Won Gu Kim, Celine J. Guigon, Laura Fozzatti, Jeong Won Park, Changxue Lu, Mark C. Willingham, and Sheue-yann Cheng

Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor HPI-1 (NanoHHI) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma
Yang Xu, Venugopal Chenna, Chaoxin Hu, Hai-Xiang Sun, Mehtab Khan, Haibo Bai, Xin-Rong Yang, Qing-Feng Zhu, Yun-Fan Sun, Anirban Maitra, Jia Fan, and Robert A. Anders

IMAGING, DIAGNOSIS, PROGNOSIS

[18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells
Cathy C. Zhang, Zhengming Yan, Wenlin Li, Kyle Kuszpit, Cory L. Painter, Qin Zhang, Patrick B. Lappin, Tim Nichols, Maruja E. Lira, Timothy Affolter, Neeta R. Fahey, Carleen Cullinane, Mary Spilker, Kenneth Zasadny, Peter O'Brien, Dana Buckman, Anthony Wong, and James G. Christensen
See commentary p. 1189

Epidermal Growth Factor Receptor Protein Detection in Head and Neck Cancer Patients: A Many-Faceted Picture
Juliette Thariat, Marie-Christine Etienne-Grimaldi, Dominique Grall, René-Jean Bensadoun, Anne Cayre, Frédérique Penault-Llorca, Laurence Veracini, Mireille Francoul, Jean-Louis Formento, Olivier Dassonneville, Dominique De Raucourt, Lionel Geoffrois, Philippe Giraud, Saverine Racadot, Sylvain Morinière, Gérard Milano, and Ellen Van Obberghen-Schilling

Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer
Markus Riester, Jennifer M. Taylor, Andrew Feifer, Theresa Koppie, Jonathan E. Rosenberg, Robert J. Downey, Bernard H. Bochner, and Franziska Michor

Copy Number Losses Define Subgroups of Dedifferentiated Liposarcoma with Poor Prognosis and Genomic Instability
Aimee M. Crago, Nicholas D. Socci, Penelope DeCarolis, Rachael O’Connor, Barry S. Taylor, Li-Xuan Qin, Cristina R. Antonescu, and Samuel Singer

Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling
Hatem A. Azim Jr, Stefan Michiels, Philippe L. Bedard, Sandeep K. Singhal, Carmen Criscitiello, Michail Ignatiadis, Benjamin Haibe-Kains, Martine J. Piccart, Christos Sotiou, and Sherene Loi

Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer
Timothy R. Donahue, Linh M. Tran, Reginald Hill, Yunfeng Li, Anne Kovochich, Joseph H. Calvopina, Sanjeev G. Patel, Napning Wu, Anreas Hindoyan, James J. Farrell, Xinmin Li, David W. Dawson, and Hong Wu

High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghu N. Sharma, John F. Thompson, Richard F. Kefford, Peter Hersey, and Richard A. Scolyer
See commentary p. 1192

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Andres Forero-Torres, Sven de Vos, Brad L. Pohliman, Maksim Pashkevich, Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Barrett W. Allan, James G. Nelson, Christopher A. Slapak, Mitchell R. Smith, Brian K. Link, James E. Wooldridge, and Kristen N. Ganjoo

Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
David S. Yoo, John P. Kirkpatrick, Oma Craciunescu, Gloria Broadwater, Bercedis L. Peterson, Madeline D. Carroll, Robert Clough, James R. MacFall, Jenny Hoang, Richard L. Scher, Ramon M. Esclamado, Frank R. Dunphy, Neal E. Ready, and David M. Brizel

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
Kimberly Noonan, Lakshmi Rudraraju, Ozma Craciunescu, Gloria Broadwater, Bercedis L. Peterson, Madeline D. Carroll, Robert Clough, James R. MacFall, Jenny Hoang, Richard L. Scher, Ramon M. Esclamado, Frank R. Dunphy, Neal E. Ready, and David M. Brizel

A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck
ABOUT THE COVER

Following treatment with a G-quadruplex ligand, telomestatin, glioma stem cells rapidly developed punctate nuclear 53BP1 foci. Of note, some of these foci colocalized with nontelomeric DNA, thereby representing both telomeric and nontelomeric dysfunction-induced foci, a hallmark of deprotected DNA damage. The loss of tumor stemness is likely associated with a failure in the DNA damage response elicited by telomestatin in glioma stem cells. For details, see the article by Miyazaki and colleagues on page 1268 of this issue.